PT856520E - Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico - Google Patents

Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico

Info

Publication number
PT856520E
PT856520E PT97203769T PT97203769T PT856520E PT 856520 E PT856520 E PT 856520E PT 97203769 T PT97203769 T PT 97203769T PT 97203769 T PT97203769 T PT 97203769T PT 856520 E PT856520 E PT 856520E
Authority
PT
Portugal
Prior art keywords
monoclonal antibody
antigens
cells
preparing
pharmaceutical composition
Prior art date
Application number
PT97203769T
Other languages
English (en)
Inventor
Steenbakkers Petrus G Antonius
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PT856520E publication Critical patent/PT856520E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/163Animal cells one of the fusion partners being a B or a T lymphocyte
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
PT97203769T 1996-12-06 1997-12-02 Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico PT856520E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203465 1996-12-06
EP97201972 1997-06-27

Publications (1)

Publication Number Publication Date
PT856520E true PT856520E (pt) 2006-08-31

Family

ID=26143410

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97203769T PT856520E (pt) 1996-12-06 1997-12-02 Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico

Country Status (17)

Country Link
US (3) US6020170A (pt)
EP (1) EP0856520B1 (pt)
JP (1) JPH10179160A (pt)
KR (1) KR100543053B1 (pt)
AT (1) ATE322507T1 (pt)
AU (1) AU733165B2 (pt)
BR (1) BR9706236A (pt)
CA (1) CA2221682C (pt)
DE (1) DE69735621T2 (pt)
DK (1) DK0856520T3 (pt)
ES (1) ES2262170T3 (pt)
HU (1) HUP9702359A3 (pt)
IL (1) IL122233A (pt)
NO (1) NO327047B1 (pt)
NZ (1) NZ329314A (pt)
PL (1) PL193821B1 (pt)
PT (1) PT856520E (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037503A1 (en) * 1998-12-22 2000-06-29 Raven Biotechnologies, Inc. Compositions and methods for generating monoclonal antibodies representative of a specific cell type
SE9902817D0 (sv) 1999-07-30 1999-07-30 A & Science Invest Ab A method for selective electrofusion of at least two fusion partners having cell-like membranes
CA2386398A1 (en) * 1999-10-18 2001-04-26 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
EP1319184B1 (en) 2000-08-14 2007-07-25 N.V. Organon Use of antibodies against specific mhc-peptide complexes
JP2006508014A (ja) * 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
US7018819B2 (en) * 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
KR20060002879A (ko) * 2003-03-28 2006-01-09 자이단호진 토야마켄 신세키 산교기코 1개의 항원 특이적 b림프구를 이용한 항원 특이적 항체를생산하는 하이브리도마의 제조방법 및 단일 클론 항체의제조방법
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
AU2005325801A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
EP2240108B1 (en) * 2008-01-09 2015-04-29 Alcon LenSx, Inc. Photodisruptive laser fragmentation of tissue
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0255547A1 (en) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
US5473051A (en) * 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
DK0488470T3 (da) * 1990-11-26 1997-12-22 Akzo Nobel Nv Fremgangsmåde til fremstilling af antistoffer
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins

Also Published As

Publication number Publication date
NO975714L (no) 1998-06-08
CA2221682A1 (en) 1998-06-06
EP0856520A1 (en) 1998-08-05
HUP9702359A2 (hu) 1998-09-28
AU733165B2 (en) 2001-05-10
IL122233A0 (en) 1998-04-05
EP0856520B1 (en) 2006-04-05
NO975714D0 (no) 1997-12-05
NZ329314A (en) 1999-02-25
JPH10179160A (ja) 1998-07-07
HU9702359D0 (en) 1998-03-02
KR19980063909A (ko) 1998-10-07
US6020170A (en) 2000-02-01
ES2262170T3 (es) 2006-11-16
MX9709446A (es) 1998-07-31
ATE322507T1 (de) 2006-04-15
DK0856520T3 (da) 2006-07-31
NO327047B1 (no) 2009-04-14
KR100543053B1 (ko) 2006-06-13
DE69735621T2 (de) 2006-08-24
IL122233A (en) 2001-04-30
AU4690897A (en) 1998-06-11
PL323572A1 (en) 1998-06-08
PL193821B1 (pl) 2007-03-30
HUP9702359A3 (en) 2001-11-28
DE69735621D1 (de) 2006-05-18
BR9706236A (pt) 1999-05-04
US20020143150A1 (en) 2002-10-03
US6392020B1 (en) 2002-05-21
CA2221682C (en) 2011-10-18

Similar Documents

Publication Publication Date Title
PT856520E (pt) Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico
DE69133179D1 (de) Katalytische antikörperkomponente
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
AU648591B2 (en) Hydrophilic polypeptide spacer
ATE268818T1 (de) Ctla4-mutantmoleküle und deren verwendung
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ATE196607T1 (de) Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper
PT733069E (pt) Antigenios ctla-8 de primata purificados e reagentes relacionados
BR9809656A (pt) Composição imunopotencializante
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DE69834808D1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
ATE317269T1 (de) Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)
ES2056919T3 (es) Anticuerpo monoclonal especifico para la fosfolipasa a2 pancreatica humana.
OA08334A (fr) Protéines de différentiation acino-foetales associées au cancer du pancréas, antisérum et anticorps monoclonaux contre ces protéines, procédés de préparation.
DE69020914D1 (de) Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.
NO874405L (no) Fremgangsmaate til bestemmelse av naervaer av diagnostisk relevante stoffer, spesielt antistoffer eller antigener etter elisa-metoden ved fotometrisk vurdering.
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.
ATE239754T1 (de) An nukleinsäure gebundenes polypeptid, verfahren zur herstellung eines an nukleinsäure gebundenen polypeptides und immunoassay, in dem dieses polypeptid verwendung findet